To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Government Operations and Politics119-hr679 — To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.. Sponsored by Rep. Harshbarger, Diana [R-TN-1]. Introduced 2025-01-23. House bill. 119th Congress. Latest action: Referred to the House Committee on Energy and Commerce.
- Sponsor
- Rep. Harshbarger, Diana [R-TN-1] (R), TN
- Introduced
- 2025-01-23
- Committees
- Energy and Commerce Committee
- Subjects
- Abortion; Drug safety, medical device, and laboratory regulation; Drug therapy; Prescription drugs
- Latest Action
- Referred to the House Committee on Energy and Commerce.
No roll-call vote data available for this bill.
Similar Bills
- 114-hr5199 — Construction Consensus Procurement Improvement Act of 2015 94% match 114th Congress
- 114-s1526 — Design-Build Efficiency and Jobs Act of 2015 68% match 114th Congress
- 114-hr1666 — Construction Consensus Procurement Improvement Act of 2015 59% match 114th Congress
- 113-s2652 — Design-Build Efficiency and Jobs Act of 2014 53% match 113th Congress
- 115-s2113 — Construction Consensus Procurement Improvement Act of 2017 40% match 115th Congress
Investigate this bill →
Beneficiary scoring, topic classification, and fiscal analysis